{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T09:05:57Z","timestamp":1790067957059,"version":"4.0.1"},"reference-count":38,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Tebentafusp is a first-in-class bispecific fusion protein that redirects T cells toward gp100-expressing cells and represents the first systemic treatment shown to improve overall survival in patients with HLA-A*02:01-positive metastatic uveal melanoma. As gp100 is also expressed on normal cutaneous melanocytes, skin toxicity is one of the most common adverse effects of treatment, although it remains relatively underrecognized. This narrative review summarizes the available evidence regarding tebentafusp-related cutaneous toxicity from clinical trials and emerging real-world studies. Across published cohorts, cutaneous adverse events occur in most patients receiving tebentafusp. They typically manifest within hours of the initial infusions as diffuse, frequently photodistributed erythematous eruptions accompanied by pruritus, with both frequency and severity generally decreasing with subsequent treatment. Other reported manifestations include xerosis, edema, pigmentary and hair alterations, including vitiligo-like depigmentation and poliosis, as well as less common urticarial, bullous, and photosensitive reactions. Although the development of early cutaneous toxicity has repeatedly been linked to better survival outcomes, this relationship does not appear to be independent of established prognostic variables. Accordingly, rash should currently be interpreted as a potential indicator of immune activation rather than a validated surrogate for therapeutic efficacy. Most cutaneous reactions are mild and can be effectively managed with emollients, topical corticosteroids, and antihistamines, while permanent discontinuation of therapy is uncommon. With tebentafusp becoming increasingly integrated into routine clinical practice and other gp100-targeted and bispecific T-cell\u2013engaging therapies entering development, recognition of this characteristic dermatologic toxicity profile and early involvement of dermatology will be important for effective supportive care and continuation of treatment. Further prospective studies using standardized terminology are warranted to better define the incidence, prognostic relevance, and optimal management of these cutaneous adverse events.<\/jats:p>","DOI":"10.3390\/cancers18193071","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T08:17:54Z","timestamp":1790065074000},"page":"3071","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dermatologic Toxicities Associated with Tebentafusp for Uveal Melanoma: A Review of Clinical Trials and Real-World Evidence"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1156-7139","authenticated-orcid":false,"given":"Ioannis-Alexios","family":"Koumprentziotis","sequence":"first","affiliation":[{"name":"Department of Dermatology and Venereology, Medical School, National and Kapodistrian University of Athens, \u201cA. Sygros\u201d Hospital for Skin and Venereal Diseases, 16121 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6322-5037","authenticated-orcid":false,"given":"Aikaterini","family":"Bakella","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, Medical School, National and Kapodistrian University of Athens, \u201cA. Sygros\u201d Hospital for Skin and Venereal Diseases, 16121 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9340-9152","authenticated-orcid":false,"given":"Vasiliki","family":"Nikolaou","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, Medical School, National and Kapodistrian University of Athens, \u201cA. Sygros\u201d Hospital for Skin and Venereal Diseases, 16121 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7074-2374","authenticated-orcid":false,"given":"Dimitra","family":"Koumaki","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, Medical School, National and Kapodistrian University of Athens, \u201cAttikon\u201d General University Hospital, 12462 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Rogala, P., Czarnecka, A.M., Dudzisz-\u015aled\u017a, M., Dawidowska, A., Piwowarek, K.J., and Rutkowski, P. (2026). Current Treatment Standards for Metastatic Uveal Melanoma. Cancers, 18.","DOI":"10.3390\/cancers18030475"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41572-020-0158-0","article-title":"Uveal melanoma","volume":"6","author":"Jager","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/PAT.0b013e32835c6505","article-title":"Pathology and genetics of uveal melanoma","volume":"45","author":"Griewank","year":"2013","journal-title":"Pathology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/nature07586","article-title":"Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi","volume":"457","author":"Bezrookove","year":"2009","journal-title":"Nature"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ccell.2017.07.003","article-title":"Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma","volume":"32","author":"Robertson","year":"2017","journal-title":"Cancer Cell"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1002\/cncr.29727","article-title":"Uveal melanoma: From diagnosis to treatment and the science in between","volume":"122","author":"Chattopadhyay","year":"2016","journal-title":"Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1159\/000543151","article-title":"Uveal Melanoma: 5-Year Update on Incidence, Treatment, and Survival (SEER 1975\u20132020)","volume":"11","author":"Weinberger","year":"2025","journal-title":"Ocul. Oncol. Pathol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/j.ophtha.2011.01.040","article-title":"Uveal melanoma: Trends in incidence, treatment, and survival","volume":"118","author":"Singh","year":"2011","journal-title":"Ophthalmology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1136\/bjophthalmol-2016-309034","article-title":"Metastatic disease from uveal melanoma: Treatment options and future prospects","volume":"101","author":"Carvajal","year":"2017","journal-title":"Br. J. Ophthalmol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1200\/JCO.20.00550","article-title":"Nivolumab Plus Ipilimumab for Treatment-Na\u00efve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402)","volume":"39","author":"Piulats","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s41571-022-00714-1","article-title":"Advances in the clinical management of uveal melanoma","volume":"20","author":"Carvajal","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2675068","DOI":"10.1080\/21645515.2026.2675068","article-title":"Tebentafusp (IMCgp100), a first in class immune-mobilizing monoclonal T-cell receptors against cancer (ImmTAC) for HLA-A*02:01 positive uveal melanoma: Product review","volume":"22","author":"Cohen","year":"2026","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Damato, B.E., Dukes, J., Goodall, H., and Carvajal, R.D. (2019). Tebentafusp: T Cell Redirection for the Treatment of Metastatic Uveal Melanoma. Cancers, 11.","DOI":"10.3390\/cancers11070971"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/imm.12779","article-title":"Polyfunctional response by ImmTAC (IMCgp100) redirected CD8+ and CD4+ T cells","volume":"152","author":"Boudousquie","year":"2017","journal-title":"Immunology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","article-title":"Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma","volume":"385","author":"Nathan","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.1158\/1078-0432.CCR-25-1513","article-title":"Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients","volume":"31","author":"Sato","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2374647","DOI":"10.1080\/21645515.2024.2374647","article-title":"Efficacy and safety of tebentafusp in patients with metastatic uveal melanoma: A systematic review and meta-analysis","volume":"20","author":"Dian","year":"2024","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s40257-017-0336-3","article-title":"Dermatologic Reactions to Immune Checkpoint Inhibitors: Skin Toxicities and Immunotherapy","volume":"19","author":"Sibaud","year":"2018","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1159\/000536332","article-title":"Quality of Life Impact in Patients with Cutaneous Toxicities Caused by Epidermal Growth Factor Receptor Inhibitors and Immunotherapy","volume":"240","author":"Mannino","year":"2024","journal-title":"Dermatology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","article-title":"Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab","volume":"152","author":"Hua","year":"2016","journal-title":"JAMA Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2014.57.4756","article-title":"Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: A systematic review and meta-analysis","volume":"33","author":"Teulings","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s40257-026-01041-2","article-title":"Dermatologic Adverse Events Associated with T-Cell Engager Therapy","volume":"27","author":"Patil","year":"2026","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"5869","DOI":"10.1158\/1078-0432.CCR-20-1247","article-title":"Tebentafusp, A TCR\/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma","volume":"26","author":"Middleton","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1038\/s41591-022-02015-7","article-title":"Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: A phase 2 trial","volume":"28","author":"Carvajal","year":"2022","journal-title":"Nat. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1056\/NEJMoa2304753","article-title":"Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma","volume":"389","author":"Hassel","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e006747","DOI":"10.1136\/jitc-2023-006747","article-title":"Tebentafusp in combination with durvalumab and\/or tremelimumab in patients with metastatic cutaneous melanoma: A phase 1 study","volume":"11","author":"Hamid","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.jaad.2025.06.020","article-title":"Severity and progression of dermatologic adverse events associated with tebentafusp: A retrospective multicenter cohort study","volume":"93","author":"Riew","year":"2025","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e181464","DOI":"10.1172\/JCI181464","article-title":"Tebentafusp elicits on-target cutaneous immune responses driven by cytotoxic T cells in uveal melanoma patients","volume":"135","author":"Staeger","year":"2025","journal-title":"J. Clin. Investig."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.jid.2024.03.048","article-title":"Tebentafusp Induces a T-Cell-Driven Rash in Melanocyte-Bearing Skin as an Adverse Event Consistent with the Mechanism of Action","volume":"145","author":"Hassel","year":"2025","journal-title":"J. Invest. Dermatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.jaad.2024.08.037","article-title":"Clinical and pathological characterization of tebentafusp-associated skin toxicity: A cohort study with 33 patients","volume":"91","author":"Tomsitz","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_31","first-page":"e47","article-title":"Dermatological Toxicities of Tebentafusp, a New Bispecific Drug: Case Series and Literature Review","volume":"67","year":"2026","journal-title":"Australas. J. Dermatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/ced\/llaf426","article-title":"Cutaneous toxicities in patients with metastatic uveal melanoma receiving tebentafusp: A retrospective review. The experience of a single large specialist institution","volume":"51","author":"Wang","year":"2026","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"adv41297","DOI":"10.2340\/actadv.v104.41297","article-title":"Efficacy and Tolerability of Tebentafusp in Metastatic Uveal Melanoma: A Real-life Retrospective Multicentre Study","volume":"104","author":"Vitek","year":"2024","journal-title":"Acta Derm. Venereol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1093\/ced\/llad387","article-title":"Cutaneous adverse effects induced by tebentafusp in patients with metastatic uveal melanoma: A case series and treatment insights","volume":"49","author":"Rodriguez","year":"2024","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/CMR.0000000000001078","article-title":"Tebentafusp-associated dermatological adverse events in patients with metastatic uveal melanoma: A single-center retrospective cohort study","volume":"36","author":"Zhou","year":"2026","journal-title":"Melanoma Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/ced\/llae427","article-title":"Early poliosis- and vitiligo-like depigmentation as an indicator of treatment response in patients with uveal melanoma under tebentafusp therapy","volume":"50","author":"Helf","year":"2025","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e207","DOI":"10.1111\/jdv.18625","article-title":"Drug-induced photosensitivity during tebentafusp treatment for metastatic uveal melanoma: A newly described occurrence","volume":"37","author":"Lambertini","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e279","DOI":"10.1111\/ajd.13866","article-title":"A review of the cutaneous toxicities of tebentafusp-Featuring two cases involving superficial bullous reactions","volume":"63","author":"Pham","year":"2022","journal-title":"Australas. J. Dermatol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/19\/3071\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T08:34:39Z","timestamp":1790066079000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/19\/3071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":38,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["cancers18193071"],"URL":"https:\/\/doi.org\/10.3390\/cancers18193071","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]}}}